Quantcast

Latest monogenic diseases Stories

2014-09-10 08:29:47

Timeline for Hemophilia B IND Application Filing Targeting Second Quarter 2015 RICHMOND, Calif., Sept. 10, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced plans to submit an Investigational New Drug (IND) application for the treatment of hemophilia B in the second quarter of 2015. This program, partnered with Shire, is the first therapeutic application of Sangamo's zinc finger nuclease (ZFN)-mediated In Vivo Protein Replacement Platform (IVPRP). Sangamo is...

2014-06-19 08:28:26

RICHMOND, Calif., June 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the appointment of H. Stewart Parker to the Company's Board of Directors. Ms. Parker, who founded and served as President and CEO of Targeted Genetics Corporation, brings more than 30 years of experience in the biotechnology industry, including 16 years of specific experience in cell and gene therapy. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO "We are very pleased to...

2014-05-28 16:26:41

Groundbreaking Nature Publication Describes Successful ZFN Driven Genome Editing in Long-Term Repopulating Stem Cells Necessary for Clinical Translation RICHMOND, Calif., May 28, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication in Nature of data demonstrating efficient zinc finger nuclease (ZFN)-mediated, targeted gene insertion that resulted in correction of the genetic defect in stem cells from an individual with X-linked severe combined...

2014-05-14 08:31:21

RICHMOND, Calif., May 14, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics(®) will be presented at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Fourteen oral and poster presentations, given by Sangamo scientists and their academic collaborators, will detail data from Sangamo's therapeutic and research programs...

2014-01-08 08:27:43

RICHMOND, Calif., Jan. 8, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and chief executive officer, will present an update on Sangamo's clinical and preclinical ZFP Therapeutic(®) programs and upcoming milestones, as well as an overview of the Company's business strategy at the 32(nd) Annual J.P. Morgan Healthcare Conference on Thursday, January 16(th) at 11:00 am PT in San Francisco. (Logo:...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'